• Eric Schadt: Why Biology Needs a Steve Jobs

    Nature Biotechnology | Eric Schadt, director of Mount Sinai's new Institute for Genomics and Multiscale Biology, discusses his vision to spend $100 million launching Mount Sinai to the forefront of the genomics revolution—and why he's enlisting Wall Street quants, user interface gurus and Facebook's former data whiz to do it.

    Aug 9, 2012

  • Nic Volker, Living on the Edge of Science

    JS Online | Two years after exome sequencing prompted a life-saving cord blood transplant, 7-year-old Wisconsinite Nic Volker is enjoying school, real food, good health and life in general. 

    Aug 9, 2012

  • Clinical Trial is Favorable for Microarray Prenatal Gene Test

    New York Times | The use of microarrays for prenatal testing to detect more genetic problems in a fetus than standard kayrotype testing could be headed toward wider use after encouraging results from an NIH-sponsored clinical trial of more than 4,000 pregnancies.  

    Aug 9, 2012

  • Physicians May Not Be Social, But They are Interactive

    Forbes.com | The desire to understand physician behavior, identify Key Opinion Leaders, and reach those influencers in a measured way is of extreme importance to pharmaceutical executives, writes Jim Golden in his latest blog.  

    Aug 9, 2012

  • CardioDx Wins Medicare OK of Molecular Test for Heart Disease

    Xconomy | After three years marketing a new genetic test that can tell when a patient’s chest pain is a sign of serious heart disease, CardioDX has taken a big step forward by persuading Palmetto GBA, the national contractor for Medicare, to reimburse the company for its Corus CAD test.

    Aug 8, 2012

  • Congratulations on Reaching the $1000 Genome

    PolITigenomics | For all intents and purposes, argues David Dooling, we have already achieved the $1,000 human genome -- compared to the $1 billion or spent on the first human genome, the difference between $1,000 and $5,000 is just a rounding error. "So, congratulations, we did it!"

    Aug 6, 2012

  • Quinten’s Savoir Faire Approach to Data Mining

    Bio-IT World | Quinten, a rapidly expanding French CRO, brings an innovative data-mining approach to much of the drug development pipeline – from early stage target identification to clinical trials and patient stratification. Here, Kevin Davies interviews Quinten CEO Alexandre Templier. 

    Aug 3, 2012

  • Drug Discovery Looks for Its Next Fix

    HPC Wire | Supercomputing shows great promise to improve the process of drug discovery, not only to find better, safer drugs, but also to weed out those compounds that would eventually fail during clinical trials. 

    Aug 3, 2012

  • Five Steps for Handling your Big Data Hoard

    Enterprise CIO Forum | Decades ago, valued data was handled in a very manual and individual manner. But the explosion of data sources has made most people hoarders, without a plan to leverage the value. 

    Aug 3, 2012

  • Russian Web Tycoon Launches World's Biggest Science Prize

    The Guardian | Yuri Milner, a Russian internet investor who quit his PhD in physics and made $1 billion investing in social networking firms such as Facebook, Twitter and Groupon, has launched a clutch of awards worth $3 million apiece to recognise advances in fundamental physics.

    Jul 31, 2012

  • 23andMe Seeks FDA Approval for Personal DNA Test

    Bloomberg Businessweek | Consumer genetics pioneer 23andMe has taken the first step towards seeking Food and Drug Administration approval of its personalized DNA test.  

    Jul 30, 2012

  • Sharp Dip in US Drug Approvals Forecast

    Pharma Times | The US Food and Drug Administration (FDA) will approve fewer novel drugs in 2012 than it did last year, as the industry faces a number of ongoing operational risks, according to a new report.

    Jul 30, 2012

  • A New Chapter for the Consumer Genetics Conference

    Bio-IT World | Asked what prompted her to launch The Consumer Genetics Conference (CGC) three years ago, together with her friend John Boyce, Meredith Salisbury says simply, “Insanity.” Coming to their senses, the duo have partnered with CHI to produce the 2012 conference, which will be held October 3-5, 2012. 

    Jul 27, 2012

  • Complete Genomics Bundles Ingenuity Variant Analysis software

    Bio-IT World | Complete Genomics announced that it will bundle Ingenuity Systems’ Variant Analysis application with its research whole genome sequencing services.

    Jul 26, 2012

  • John Reynders on the Role of R&D Information at AstraZeneca

    Bio-IT World | In his current role as head of R&D Information at AstraZeneca, John Reynders discusses the breadth of skills among his 400-strong team and the company’s commitment to innovation and long-range strategic planning. 

    Jul 24, 2012

  • Lasker Foundation Begins Search for Next President

    Bio-IT World | The Albert and Mary Lasker Foundation has embarked upon a global search for its next president to lead its operations, succeeding current chief Maria Freire, who is leaving this Fall. 

    Jul 24, 2012

  • 23andMe DNA Mapping Reunites Long-Lost Siblings

    CBS This Morning | Given up for adoption in 1960 at just 10 days, Neil Schwartzman suddenly traced his long-lost biological sister through the online DNA genotyping services of consumer genetics company 23andMe.

    Jul 24, 2012

  • Ion Torrent Named First Entrant in Genomics X Prize Competition

    Bio-IT World | Organizers of the $10-million Archon Genomics X PRIZE competition, presented by Express Scripts, hope that the official entry of Ion Torrent will spur other next-gen sequencing hopefuls to sign up before the contest is held in September 2013.

    Jul 22, 2012

  • New York Genome Center Inks Lease on 6th Avenue

    The Commercial Observer | The New York Genome Center has reportedly completed a deal to lease 150,000 square feet at 101 Avenue of the Americas.

    Jul 20, 2012

  • Human Genes as Company Property Tested by Myriad Patent Case

    Bloomberg Businessweek | Madeleine Ball, a Harvard University geneticist, says entire regions of the human genome are at risk of becoming inaccessible to anyone who can’t afford to pay for patent licenses, stifling the information-sharing that is vital to scientific progress.

    Jul 19, 2012